Clinical trial
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
NCT01683175
Study timeline
Study start (unknown)2012-08-01Date precision: month
Registry last updated2016-10-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancer Stage IIIunresolved
Interventions
ErlotinibDRUG · verified · RxNorm: erlotinib
cis-platinumDRUG
VinorelbineDRUG · verified · RxNorm: vinorelbine
Sponsors & collaborators
Roche Pharma AGcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01683175 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.